Additional Hetero Ring Attached Directly Or Indirectly To The Diazole Ring By Nonionic Bonding (e.g., Methyl( 5-[2-(2-thienyl)-1,3-dioxolan -2-yl]-1h-benzimidazol-2-yl) Carbamate, Etc.) Patents (Class 548/304.7)
  • Patent number: 6696437
    Abstract: The present invention relates to novel benzimidazoles, their preparation and their use as inhibitors of the enzyme poly(ADP-ribose) polymerase or PARP (EC 2.4.2.30) for producing drugs.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: February 24, 2004
    Assignee: Abbott GmbH & Co. KG
    Inventors: Wilfried Lubisch, Michael Kock, Thomas Hoeger, Roland Grandel, Uta Holzenkamp, Sabine Schult, Reinhold Mueller
  • Publication number: 20040034078
    Abstract: Compounds of formula I are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used in combination with cytotoxic agents and/or radiation.
    Type: Application
    Filed: June 4, 2003
    Publication date: February 19, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Donald J. Skalitzky, Stephen E. Webber, Brian Eastman
  • Publication number: 20040024037
    Abstract: An antibiotic additive and an ink composition including the antibiotic additive include a compound produced by binding of an antibiotic substance having the following formula (I) to a predetermined additive via a chemical reaction. The ink composition includes a colorant, a solvent and an antibiotic additive produced by binding of an antibiotic substance having the following formula (I) to a predetermined additive via a chemical reaction. The antibiotic additive prevents surface dry, improves storage stability and inhibits propagation and growth of bacteria in an ink and has excellent compatibility with a general dye or pigment.
    Type: Application
    Filed: July 2, 2003
    Publication date: February 5, 2004
    Applicant: SAMSUNG Electronics Co., Ltd.
    Inventors: Seung-Min Ryu, Jae-Hwan Kim, Jong In Lee, Dae Hee Lee
  • Publication number: 20040009995
    Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1
    Type: Application
    Filed: May 28, 2003
    Publication date: January 15, 2004
    Applicant: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Rae Hufnagel, Jeremy M. Travins, Shelley K. Ballentine, Kenneth T. Wilson, Maxwell D. Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, M. Jonathan Rudolph, Hui Huang
  • Publication number: 20040006104
    Abstract: The invention provides novel compounds selected from the group consisting of: 1
    Type: Application
    Filed: February 18, 2003
    Publication date: January 8, 2004
    Applicant: The Procter & Gamble Company
    Inventors: Rodney Dean Bush, Paul Mitchell Hershberger, Judith Anne Young, Bhavani Kasibhatla
  • Publication number: 20040002524
    Abstract: This invention relates to compounds, in particular benzimidazoles, that are useful as estrogen agonists and/or antagonists and pharmaceutical uses thereof. The present invention also relates to benzimidazoles that are selective for the ER&bgr; receptor and pharmaceutical uses thereof.
    Type: Application
    Filed: June 11, 2003
    Publication date: January 1, 2004
    Inventors: Richard Chesworth, Laura D. Gegnas
  • Publication number: 20030232816
    Abstract: A compound of the formula I: 1
    Type: Application
    Filed: September 10, 2002
    Publication date: December 18, 2003
    Applicant: Boehringer Ingelheim (Canada) Ltd.
    Inventors: Pierre Louis Beaulieu, Gulrez Fazal, James Gillard, George Kukolj, Volkhard Austel
  • Publication number: 20030232869
    Abstract: Disclosed are compounds of the formula I 1
    Type: Application
    Filed: March 13, 2003
    Publication date: December 18, 2003
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
  • Publication number: 20030229085
    Abstract: New benzimidazole derivatives are described, their production and their use for the production of pharmaceutical agents for treatment and prevention of diseases that are associated with a microglia activation and T-cell-mediated immunological diseases, as well as pharmaceutical preparations that contain the new benzimidazole derivatives.
    Type: Application
    Filed: February 14, 2003
    Publication date: December 11, 2003
    Applicant: Schering Aktiengesellschaft
    Inventors: Thorsten Blume, Wolfgang Halfbrodt, Joachim Kuhnke, Ursula Moenning, Bernd Elger, Herbert Schneider
  • Publication number: 20030225053
    Abstract: Disclosed are amide compounds of formula(I): 1
    Type: Application
    Filed: April 10, 2003
    Publication date: December 4, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Donghong Amy Gao, Daniel R. Goldberg, Abdelhakim Hammach, Ming-Hong Hao, Victor Marc Kamhi, Neil Moss, Kevin Chungeng Qian, Gregory Paul Roth, Christopher Ronald Sarko, Alan David Swinamer, Zhaoming Xiong
  • Publication number: 20030225091
    Abstract: Compounds that are dual aP2/k-FABP inhibitors are provided having the formula 1
    Type: Application
    Filed: November 15, 2002
    Publication date: December 4, 2003
    Inventors: David R. Magnin, Richard B. Sulsky, Jeffrey A. Robl, Thomas J. Caulfield, Rex A. Parker
  • Publication number: 20030212012
    Abstract: The present invention is related to pyrrolidine derivatives of formula (I).
    Type: Application
    Filed: February 10, 2003
    Publication date: November 13, 2003
    Inventors: Serge Halazy, Anna Quattropani, Alexander Scheer, Mattias Schwarz, Russell Thomas, Antony Baxter
  • Publication number: 20030207868
    Abstract: The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.
    Type: Application
    Filed: December 4, 2002
    Publication date: November 6, 2003
    Inventors: Kuo-Long Yu, Xiangdong Wang, Yaxiong Sun, Christopher Cianci, Jan Willem Thuring, Keith Combrink, Nicholas Meanwell, Yi Zhang, Rita L. Civiello
  • Publication number: 20030195239
    Abstract: Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.
    Type: Application
    Filed: March 31, 2003
    Publication date: October 16, 2003
    Applicant: Pfizer Inc.
    Inventors: Allen J. Borchardt, Michael Paul Goble
  • Patent number: 6632809
    Abstract: The present invention relates to compounds of the formula I: or a pharmaceutically acceptable derivative or prodrug thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treating bacterial infections in mammala. The present invention also relates to methods for decreasing bacterial quantity in a biological sample.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: October 14, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Anne-Laure Grillot, Paul Charifson, Dean Stamos, Yusheng Liao, Michael Badia, Martin Trudeau
  • Publication number: 20030191139
    Abstract: The invention relates to compounds of formula I D—CO—B—A-Het and pharmaceutically acceptable salts thereof where substituents in description have the specified meanings. The compounds are used as thrombin inhibitors.
    Type: Application
    Filed: January 31, 2003
    Publication date: October 9, 2003
    Inventors: Danijel Kikelj, Lucija Peterlin, Petra Marinko, Matej Breznik, Mojca Stregnar, Bakija Alenka Trampuz, Marjana Fortuna
  • Patent number: 6627624
    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein the A, B, C, D, X, R1, R2, R3, R4, R5, and R6, are variables defined herein, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, depression, overdose with benzodiazepine drugs, and enhancement of memory and alertness.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: September 30, 2003
    Assignee: Neurogen Corporation
    Inventors: Robert W. DeSimone, Alan Hutchison, Kenneth Shaw, Daniel L. Rosewater
  • Publication number: 20030171309
    Abstract: The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerative disorders, diseases associated with polygultamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders renal hypoxia, hepatitis and AIDS. Said pyrrolidine derivatives display a modulatory and most notably a down-regulating-up to an inhibitory-activity with respect to the cellular death agonist Bax and/or the activation pathways leading to Bax and allows therefore to block the release of cytochrome (c).
    Type: Application
    Filed: April 28, 2003
    Publication date: September 11, 2003
    Inventors: Serge Halazy, Anna Quattropani, Agnes Bombrun, Mattias Schwarz, Russel Thomas, Anthony Baxter
  • Patent number: 6613787
    Abstract: Asymmetric derivatives of furamidines with one of the phenyl rings of furamidine replaced with a benzimidazole have been found by quantitative footprinting analyses to bind GC containing sites on DNA more strongly than to pure AT sequences. These compounds have been shown to bind in the minor groove at specific GC containing sequences of DNA in a highly cooperative manner as a stacked dimer. Compounds of the present invention find use in selectively binding mixed sequence DNA, and may also be used in methods of regulating gene expression, methods of treating opportunistic infections and cancer, as well as in methods of detecting certain sequences of DNA.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: September 2, 2003
    Assignees: The University of North Carolina at Chapel Hill, Georgia State University Research Foundation, Inc.
    Inventors: W. David Wilson, David W. Boykin, Richard R. Tidwell
  • Publication number: 20030149018
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: December 9, 2002
    Publication date: August 7, 2003
    Applicant: Wyeth
    Inventors: Ping Zhou, Michael Gerard Kelly
  • Publication number: 20030144281
    Abstract: Disclosed are substituted benzimidazole compounds of formula(I): 1
    Type: Application
    Filed: November 5, 2002
    Publication date: July 31, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles Cywin, Jinbo Lee, Steven S. Pullen, Gregory Paul Roth, Christopher Ronald Sarko, Roger John Snow, Noel Stewart Wilson
  • Publication number: 20030134853
    Abstract: A series of compounds of Formula I are disclosed which are useful in treating viral hepatitus C.
    Type: Application
    Filed: September 26, 2002
    Publication date: July 17, 2003
    Inventors: Eldon Scott Priestley, Carl P. Decicco, Thomas W. Hudyma, Xiaofan Zheng
  • Publication number: 20030130265
    Abstract: The invention concerns benzimidazole derivatives of the general formula (I) 1
    Type: Application
    Filed: September 9, 2002
    Publication date: July 10, 2003
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Pascale Pouzet, Christoph Hoenke, Claudia Heine, Ralf Anderskewitz, Horst Dollinger, Herbert Nar, Hans Michael Jennewein, Bernd Disse
  • Publication number: 20030125550
    Abstract: The invention relates to novel benzimidazole derivatives with general formula I, whereby radicals R1, R2, R3, A, B, Y and Z have the meanings that are indicated in the description and the claims, the use of these compounds for the production of a pharmaceutical agent for treatment and prevention of diseases associated with microglia activation as well as pharmaceutical preparations that contain these compounds.
    Type: Application
    Filed: July 9, 2002
    Publication date: July 3, 2003
    Inventors: Thorsten Blume, Wolfgang Halfbrodt, Joachim Kuhnke, Ursula Monning, Herbert Schneider
  • Publication number: 20030119754
    Abstract: The present invention relates to novel benzimidazole compounds that have useful antiviral activity. More specifically, the invention encompasses benzimidazole compounds that inhibit membrane fusion associated events such as viral transmission, reduce viral load or otherwise treat viral infections. The invention also encompasses the use of benzimidazole compounds as inhibitors of membrane fusion associated events, such as viral transmission. In another embodiment, the invention encompasses processes for making benzimidazole compounds, methods of using the benzimidazole compounds and compositions comprising the benzimidazole compounds. Finally, the invention provides methods for treating, preventing or ameliorating symptoms associated with respiratory infection, particularly that caused by Respiratory Syncytial Virus utilizing the novel benzimidazole compounds of the invention.
    Type: Application
    Filed: May 9, 2002
    Publication date: June 26, 2003
    Inventors: John William Lackey, Daniel S. Kinder, Nicolai A. Tvermoes
  • Publication number: 20030109714
    Abstract: This invention relates to a transition metal mediated process for the preparation of optionally substituted 2-amino-benzoxazoles and or 2-amino-benzimidazoles, which are useful as therapeutic agents or as intermediates in the synthesis of therapeutic agents.
    Type: Application
    Filed: September 20, 2002
    Publication date: June 12, 2003
    Inventors: Neil Wishart, Alena Rudolph, Kurt Ritter
  • Publication number: 20030109550
    Abstract: The present invention relates to substituted indazole derivatives, compositions comprising such, intermediates, methods of making substituted indazolel derivatives, and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis.
    Type: Application
    Filed: September 19, 2002
    Publication date: June 12, 2003
    Inventors: Michael Clare, Joyce Z. Crich, Francis J. Koszyk, Richard A. Partis, Michael A. Stealey, Richard M. Weier, Xiangdong Xu, Cathleen E. Hanau
  • Publication number: 20030104473
    Abstract: The present invention provides common ligand mimics that act as common ligands for a receptor family. The present invention also provides bi-ligands containing these common ligand mimics. Bi-ligands of the invention provide enhanced affinity and/or selectivity of ligand binding to a receptor or receptor family through the synergistic action of the common ligand mimic and specificity ligand that compose the bi-ligand. The present invention also provides combinatorial libraries containing the common ligand mimics and bi-ligands of the invention. Further, the present invention provides methods for manufacturing the common ligand mimics and bi-ligands of the invention and methods for assaying the combinatorial libraries of the invention.
    Type: Application
    Filed: March 12, 2002
    Publication date: June 5, 2003
    Inventors: Qing Dong, Hengyuan Lang, Lan Xie, Lin Yu
  • Publication number: 20030100545
    Abstract: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
    Type: Application
    Filed: September 30, 2002
    Publication date: May 29, 2003
    Inventors: Nicholas Michael Kelly, Kristian Norup Koch, Bo-Ragnar Tolf
  • Patent number: 6569881
    Abstract: The present invention relates to a new substituted benzimidazoles, their preparation and their use as agents against parasitic protazoa.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: May 27, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Giesela Greif, Axel Haberkorn, Bernd Baasner, Folker Lieb, Albrecht Marhold, Jörn Stölting
  • Publication number: 20030078286
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: April 19, 2002
    Publication date: April 24, 2003
    Applicant: Wyeth
    Inventors: Yanfang Li, Ping Zhou
  • Publication number: 20030069278
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: April 19, 2002
    Publication date: April 10, 2003
    Applicant: Wyeth
    Inventors: Ping Zhou, Boyd Lynn Harrison, Yanfang Li
  • Publication number: 20030055057
    Abstract: The invention relates to novel benzimidazole derivatives with general formula I, whereby radicals R1, R2, R3, A, B and Y have the meanings that are indicated in the description and the claims, the use of these compounds for the production of a pharmaceutical agent for treating and for preventing diseases that are associated with microglia activation, as well as pharmaceutical preparations that contain these compounds.
    Type: Application
    Filed: July 5, 2002
    Publication date: March 20, 2003
    Applicant: Schering AG
    Inventors: Thorsten Blume, Wolfgang Halfbrodt, Joachim Kuhnke, Ursula Moenning, Herbert Schneider, Bernd Elger
  • Publication number: 20030055055
    Abstract: The present invention relates to novel benzimidazole derivatives, pharmaceutical composition containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABA receptor complex, and in particular for inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children. The compounds of the invention may also be used by veterinarians.
    Type: Application
    Filed: December 12, 2001
    Publication date: March 20, 2003
    Inventors: Lene Teuber, Frank Watjen
  • Patent number: 6534503
    Abstract: Methods for treating sexual dysfunction, such as erectile dysfunction or sexual arousal disorder, with a compound having the generic formula X1—X2-(D)Phe-Arg-(D)Trp-X3. A particularly useful compound is HP-228, which has the formula Ac-Nle-Gln-His-(D)Phe-Arg-(D)Trp-Gly-NH2. The invention also provides methods for selecting melanocortin receptor-3 ligands by determining whether a compound modulates the activity of MC-3 as an agonist or antagonist. These methods can be used to screen compound libraries for ligands to treat MC-3-associated conditions. Such conditions include sexual dysfunction, including erectile dysfunction and sexual arousal disorder.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: March 18, 2003
    Assignee: Lion Bioscience AG
    Inventors: Kevin C. Dines, Timothy C. Gahman, Beverly E. Girten, Douglas L. Hitchin, Kevin R. Holme, Hengyuan Lang, Sandra R. Slivka, Karen J. Watson-Straughan, Ronald R. Tuttle, Yazhong Pei
  • Patent number: 6528510
    Abstract: The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: March 4, 2003
    Assignee: Warner-Lambert Company
    Inventors: Frederick Earl Boyer, Jr., John Michael Domagala, Edmund Lee Ellsworth, Christopher Andrew Gajda, Susan Elizabeth Hagen, Michael James Lovdahl, Elizabeth Ann Lunney, Larry James Markoski, Josyula Venkata Nagendra Vara Prasad, Bradley Dean Tait
  • Publication number: 20020173656
    Abstract: The present invention relates to compounds of the formula I, 1
    Type: Application
    Filed: December 6, 2001
    Publication date: November 21, 2002
    Inventors: Anuschirwan Peyman, David William Will, Uwe Gerlach, Marc Nazare, Gerhard Zoller, Hans-Peter Nestler, Hans Matter, Fahad Al-Obeidi
  • Publication number: 20020156111
    Abstract: The invention is directed to physiologically active compounds of general formula (I): 1
    Type: Application
    Filed: November 2, 2001
    Publication date: October 24, 2002
    Inventors: David Edward Clark, Paul Robert Eastwood, Neil Victor Harris, Clive McCarthy, Andrew David Morley, Stephen Dennis Pickett
  • Patent number: 6448281
    Abstract: A compound of the formula I: wherein: X is CH or N; Y is O or S; Z is OH, NH2, NMeR3, NHR3; OR3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from O, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR7 or CR5, wherein R5 is H, halogen, or (C1-6) alkyl and R7 is H or (C1-6 alkyl), with the proviso that X and A are not both N; R6 is H, halogen, (C1-6 alkyl) or OR7, wherein R7 is H or (C1-6 alkyl); R1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C1-3)alkyl, (C2-6)alkenyl, phenyl(C2-6)alkenyl, (C3-6)cycloalkyl, (C1-6)alkyl, CF3, 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C2-6)alkenyl and phenyl(C1-3)alkyl), alkenyl, cycloalkyl, (C1-6)alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents; R2 is selected from (C1-6)alkyl, (C
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: September 10, 2002
    Assignee: Boehringer Ingelheim (Canada) Ltd.
    Inventors: Pierre Louis Beaulieu, Gulrez Fazal, James Gillard, George Kukolj, Volkhard Austel
  • Patent number: 6432993
    Abstract: Substituted fused heterocyclic compounds of the formula (I) and pharmacologically acceptable salts thereof: wherein R1 is a group of the formula (II) or (III): R4 is a substituted phenyl or a pyridyl which may have a substituent. R5 is hydrogen or the like. R6 is hydrogen, a C1-6 alkyl group or the like. D is oxygen or sulfur. E is a CH group or nitrogen. R2 is hydrogen or the like. R3 is a 2,4-dioxothiazolidin-5-ylmethyl group or the like. A is a C1-6 alkylene group. B is oxygen or sulfur. These compounds and salts are useful as the active ingredient of pharmaceutical compositions which can be used to treat patients because these compounds and salts have excellent insulin-resistance improving action, lipid-peroxide-production inhibitory action, 5-lipoxygenase inhibitory action and the like.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: August 13, 2002
    Assignee: Sankyo Company, Limited
    Inventors: Takashi Fujita, Kunio Wada, Toshihiko Fujiwara
  • Publication number: 20020107204
    Abstract: We have discovered a method of modifying the tumor cell microenvironment to reduce or prevent the establishment, growth or metastasis of malignant cells comprising administering to a patient having malignant cells a pharmaceutically effective amount of a PAR-1 inhibitor and optionally a PAR-2 inhibitor to prevent or reduce activation of normal cells within the tumor microenvironment. This method also has the effect in some patients of modulating the immune system to facilitate a more efficient immune response to malignant cells and maybe coupled with cytokine therapy and T-cell therapy to enhance the patient's immune response to the malignant cells.
    Type: Application
    Filed: May 25, 2001
    Publication date: August 8, 2002
    Inventors: Michael D'Andrea, Claudia Derian, Hal Brent Woodrow
  • Patent number: 6420409
    Abstract: A novel benzimidazole derivative or a salt thereof is provided, which is represented by the formula: wherein R1 represents an alkyl group, etc., R2 represents a substituted or unsubstituted aromatic lower alkyl group, R3 represents an alkyl group, etc., and -X- is represented by the following formula (V): etc. This derivative or a salt thereof is useful as medicine.
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: July 16, 2002
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Noritsugu Yamasaki, Takafumi Imoto, Teruo Oku, Akira Katayama, Hiroshi Kayakiri, Osamu Onomura, Takahiro Hiramura, Masahiro Nishikawa, Hitoshi Sawada
  • Patent number: 6420560
    Abstract: This invention relates to novel multibinding compounds (agents) that are H1 histamine receptor antagonists and pharmaceutical compositions comprising such compounds. Accordingly, the multibinding compounds and pharmaceutical compositions of this invention are useful in the treatment and prevention of allergic diseases such as rhinitis, urticaria, asthma, and anaphylaxis, and the like.
    Type: Grant
    Filed: June 7, 1999
    Date of Patent: July 16, 2002
    Assignee: Theravance, Inc.
    Inventors: Robert P. Numerof, Yu-Hua Ji, John H. Griffin
  • Patent number: 6413938
    Abstract: According to a first aspect of the invention there is provided compounds of formula (I): wherein: R1 is hydroxy; O-acetyl; or a halo atom; R2 is hydroxy; O-acetyl; or a halo atom; R3 is hydrogen; a halo atom; azido; C2-6alkenyl; C2-6alkynyl; C6-14aryl C2-6alkenyl; C6-14arylC2-6alkynyl —NR8R9 (where R8 and R9 may be the same or different and are hydrogen, C1-8alkyl, cyanoC1-8alkyl, hydroxyC1-8alkyl, haloC1-8alkyl, C3-7cycloalkyl, C1-8alkylC3-7cycloalkyl, C2-6alkenyl, C3-7cycloalkylC1-8alkyl, C2-6alkynyl, C6-14aryl, C6-14arylC1-8alkyl, heterocycleC1-8alkyl, C1-8alkylcarbonyl, C6-14arylsulfonyl, C1-8alkysulfonyl, or R8R9 together with the N atom to which they are attached form a 3,4,5 or 6 membered heterocyclic ring); —OR10 (where R10 is hydrogen, C1-8alkyl, C6-14aryl, or C6-14arylC1-8alkyl, C2-6alkenyl, C2-6alkynyl, C6-14aryl C2-6alkenyl or C6-14arylC2-6alkynyl); or —SR11 (where R11 is hydrogen, C1-8alkyl, C6-14aryl, or C6-14arylC1-8alkyl).
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: July 2, 2002
    Assignees: The Regents of the University of Michigan, Glaxo Wellcome Inc.
    Inventors: Jeffrey H. Tidwell, Stanley D. Chamberlain, George A. Freeman, Joseph H. Chan, George W. Koszalka, Leroy B. Townsend, John C. Drach
  • Patent number: 6399782
    Abstract: Novel benzimidazole compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described
    Type: Grant
    Filed: April 11, 2000
    Date of Patent: June 4, 2002
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Srinivas Rao Kasibhatla, K. Raja Reddy, Mark D. Erion, Qun Dang, Gerard R. Scarlato, M. Rami Reddy
  • Publication number: 20020065418
    Abstract: A compound of the formula I: 1
    Type: Application
    Filed: July 3, 2001
    Publication date: May 30, 2002
    Inventors: Pierre Louis Beaulieu, Gulrez Fazal, James Gillard, George Kukolj, Volkhard Austel
  • Publication number: 20020058635
    Abstract: Novel purine L-nucleoside compounds are disclosed, in which both the purine rings and the sugar are either modified, functionalized, or both. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Th1 and Th2.
    Type: Application
    Filed: October 30, 2001
    Publication date: May 16, 2002
    Inventor: Devron R. Averett
  • Publication number: 20020058678
    Abstract: Disclosed are novel aromatic heterocyclic compounds of the formula(I) wherein Ar1, Ar2, L, Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.
    Type: Application
    Filed: June 12, 2001
    Publication date: May 16, 2002
    Inventors: Pier F. Cirillo, Thomas A. Gilmore, Eugene R. Hickey, John R. Regan, Lin-Hua Zhang
  • Patent number: 6387939
    Abstract: New halogenobenzimidazoles of the formula in which A, R1, R2, R3, R4 and X have the meanings given in the description, and their acid addition salts and metal salt complexes, a process for their preparation and their use as microbicides in crop protection and in the protection of materials. New intermediates of the formulae in which R12-R17 and X have the meanings given in the description, and processes for the preparation of these substances.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: May 14, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Lutz Assmann, Albrecht Marhold, Ralf Tiemann, Klaus Stenzel
  • Patent number: 6380235
    Abstract: The present invention provides compounds and pharmaceutical formulations useful as progesterone receptor agonists and antagonists and having the general formula: wherein: A is O, S, or NR4; B is a bond between A and C═Q, or the moiety CR5R6; R4, R5, R5 are independently selected from H or optionally substituted C1 to C6 alkyl, C2 to C6 alkenyl, C2 to C6 alknyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, or heterocyclic groups, or cyclic alkyl constructed by fusing R4 and R5 to from a 5 to 7 membered ring; R1 is selected from H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, substituted alknyl, —COH, or optionally substituted —CO(C1 to C3 alkyl), —CO(aryl), —CO(C1 to C3 alkoxy), or —CO(C1 to C3 aminoalkyl) groups; R2 is selected from H, halogen, CN, NO2, or optionally substituted C1 to C6 alkyl, C1 to C6 alkoxy, or C1 to C6 aminoalkyl groups; R3 is selected from a trisubstitut
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: April 30, 2002
    Assignees: American Home Products Corporation, Ligand Pharmaceuticals, Inc.
    Inventors: Puwen Zhang, Reinhold H. W. Bender, Jay E. Wrobel, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley